Bioinformatics for cancer immunotherapy target discovery
- PMID: 25344903
- PMCID: PMC11029190
- DOI: 10.1007/s00262-014-1627-7
Bioinformatics for cancer immunotherapy target discovery
Abstract
The mechanisms of immune response to cancer have been studied extensively and great effort has been invested into harnessing the therapeutic potential of the immune system. Immunotherapies have seen significant advances in the past 20 years, but the full potential of protective and therapeutic cancer immunotherapies has yet to be fulfilled. The insufficient efficacy of existing treatments can be attributed to a number of biological and technical issues. In this review, we detail the current limitations of immunotherapy target selection and design, and review computational methods to streamline therapy target discovery in a bioinformatics analysis pipeline. We describe specialized bioinformatics tools and databases for three main bottlenecks in immunotherapy target discovery: the cataloging of potentially antigenic proteins, the identification of potential HLA binders, and the selection epitopes and co-targets for single-epitope and multi-epitope strategies. We provide examples of application to the well-known tumor antigen HER2 and suggest bioinformatics methods to ameliorate therapy resistance and ensure efficient and lasting control of tumors.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures


Similar articles
-
Integrating Bioinformatics Strategies in Cancer Immunotherapy: Current and Future Perspectives.Comb Chem High Throughput Screen. 2020;23(8):687-698. doi: 10.2174/1386207323666200427113734. Comb Chem High Throughput Screen. 2020. PMID: 32338212 Review.
-
Bioinformatics for cancer immunology and immunotherapy.Cancer Immunol Immunother. 2012 Nov;61(11):1885-903. doi: 10.1007/s00262-012-1354-x. Epub 2012 Sep 18. Cancer Immunol Immunother. 2012. PMID: 22986455 Free PMC article. Review.
-
Computational Methods for Identification of T Cell Neoepitopes in Tumors.Methods Mol Biol. 2019;1878:157-172. doi: 10.1007/978-1-4939-8868-6_9. Methods Mol Biol. 2019. PMID: 30378075
-
Bioinformatics for Cancer Immunotherapy.Methods Mol Biol. 2020;2120:1-9. doi: 10.1007/978-1-0716-0327-7_1. Methods Mol Biol. 2020. PMID: 32124308 Review.
-
Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.Immunology. 2018 Jul;154(3):331-345. doi: 10.1111/imm.12936. Epub 2018 May 8. Immunology. 2018. PMID: 29658117 Free PMC article. Review.
Cited by
-
Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer.Oncotarget. 2019 Apr 2;10(26):2515-2529. doi: 10.18632/oncotarget.26808. eCollection 2019 Apr 2. Oncotarget. 2019. PMID: 31069014 Free PMC article.
-
Bioinformatic identification of candidate biomarkers and related transcription factors in nasopharyngeal carcinoma.World J Surg Oncol. 2019 Apr 1;17(1):60. doi: 10.1186/s12957-019-1605-9. World J Surg Oncol. 2019. PMID: 30935420 Free PMC article.
-
TANTIGEN: a comprehensive database of tumor T cell antigens.Cancer Immunol Immunother. 2017 Jun;66(6):731-735. doi: 10.1007/s00262-017-1978-y. Epub 2017 Mar 9. Cancer Immunol Immunother. 2017. PMID: 28280852 Free PMC article.
-
Editorial: How pharmacogenomics, epigenetics, and data analysis could improve anticancer treatment?Front Pharmacol. 2022 Nov 10;13:1067022. doi: 10.3389/fphar.2022.1067022. eCollection 2022. Front Pharmacol. 2022. PMID: 36438848 Free PMC article. No abstract available.
-
Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.Diagn Pathol. 2016 May 18;11(1):44. doi: 10.1186/s13000-016-0494-2. Diagn Pathol. 2016. PMID: 27189072 Free PMC article.
References
-
- Rees R, Laversin S, Murray C, Ball G. Current approaches to identify and evaluate cancer biomarkers for patient stratification. In: Morrow WJW, Sheikh NA, Schmidt CS, Davies DH, editors. Vaccinology: principles and Practice. Oxford: Wiley; 2012. pp. 452–463.
-
- Blades RA, Keating PJ, McWilliam LJ, et al. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology. 1995;46:681–686. - PubMed
-
- Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–949. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous